08/27/2026
OU Health is expanding access to advanced heart valve care with the newest FDA-approved therapies for structural heart disease, offering Oklahomans more treatment options close to home.
As one of the first health systems in the region to offer the TriClip™ and Evoque™ therapies for tricuspid valve disease, and the first in Oklahoma City to perform an Abbott Navitor™ transcatheter aortic valve replacement, OU Health continues to bring leading-edge cardiovascular care to patients across the state.
These minimally invasive procedures provide new options for patients with complex heart valve conditions, often without the need for open-heart surgery.
"For years, the tricuspid valve was called the forgotten valve, and patients with severe leak were often told to live with it," said Dr. Parasuram Melarcode Krishnamoorthy, interventional cardiologist and leader of our structural heart program. "That has changed. We can now repair this valve, and we can replace it, all through a small incision in the leg. Oklahomans should not have to leave the state to receive that kind of care."
Through a coordinated team of interventional cardiologists, cardiothoracic surgeons, heart failure specialists and imaging experts, OU Health is helping patients access innovative treatments and personalized care right here in Oklahoma.
Advanced heart care. Innovative treatment options. Closer to home.